BioSpace News Archive

Inventiva announced the signing of a €50 million bullet credit facility agreement with the European Investment Bank.

Faron Pharmaceuticals Ltd. announces that both the U.S. Food and Drug Administration and Finnish Medicines Agency have cleared Faron’s Investigational New Drug application to begin the Company sponsored BEXMAB study.

Nutex Health Inc., a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, announced two new fully operational micro hospitals.

SIFI S.p.A., a leading international ophthalmic company headquartered in Italy, announced that it received favorable and supportive feedback from the United States Food and Drug Administration through a ‘Type B’ meeting held in early May regarding its potential regulatory application of AKANTIOR® for the treatment of acanthamoeba keratitis.

Celmatix Inc. a biotechnology company focused on ovarian biology, announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug.

Voyager Therapeutics, Inc. is scheduled to present findings demonstrating preclinical proof-of-concept for its vectorized anti-HER2 antibody program and cross-species translatability for its novel AAV5-derived capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting.

RadNet, Inc., announced that it has received FDA clearances for its DeepHealth Saige-DX™ mammography and Quantib® Prostate 2.0 MRI artificial intelligence algorithms.

Akari Therapeutics, Plc, a late-stage biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, announced financial results for the full year ended December 31, 2021, as well as recent pipeline progress.

Bionomics Limited announced that Dr Errol De Souza, Executive Chairman of Bionomics, will participate in three upcoming investor conferences:

Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.